A patient’s odds of receiving an unproven knee surgery depend largely on their zip code, according to a new analysis of 100 million U.S. insurance claims. Despite clinical trials showing physical therapy is often just as effective, over 500,000 meniscectomies are performed annually at a $4 billion cost.
Securing the third spot among all-inclusive resorts worldwide in the Tripadvisor Travelers' Choice Best of the Best Awards, Manta Island Resort is leveraging its newfound global prominence to debut a high-end villa collection and a specialized diving package within the protected waters of Glover's Reef Atoll.
A historic property on Jefferson Place now serves as the permanent home for the Transpacific Future Center, signaling a strategic shift toward long-term policy dialogue. Supported by a 3 million dollar endowment from Evermay, the organization aims to centralize its leadership initiatives within the nation’s capital to strengthen regional ties.
With five additional aircraft now under its control, New York-based Fundamental Advisors has acquired Southern California operator BlueSky Helicopters. The deal bolsters the investment firm's public service aviation platform, specifically targeting high-demand aerial firefighting and utility infrastructure markets across the Western United States.
With hospital operating margins dipping below 3% and insurance denial rates climbing, Boston-based startup Tally is turning to agentic AI to overhaul the complex, error-prone world of specialty healthcare billing through a new strategic partnership with the Founders' Studio Liminal.
After an eighteen-year tenure, Daybright Financial CFO Matt Riordan is stepping into a new role as Operating CFO, passing the lead financial reins to industry veteran Wes Gilbreath. The transition, effective July 20, signals a strategic shift as the firm aims to scale its national operations.
The global market for CAR T-cell therapy in non-Hodgkin lymphoma is poised for steady expansion, with projections indicating a compound annual growth rate of approximately 7% through 2036. This upward trajectory reflects a broader clinical shift from traditional chemo-immunotherapy toward specialized, cell-based treatment modalities for patients with complex disease profiles.
The global market for artificial intelligence in drug discovery is poised for a significant transformation, with projections indicating a jump from $5.09 billion in 2026 to $17.56 billion by 2031. This expansion represents a steady compound annual growth rate of 28.1% as pharmaceutical firms pivot toward integrated, data-driven R&D environments.
Investors who purchased Via Transportation shares between September 15, 2025, and May 12, 2026, have until August 10, 2026, to apply for lead plaintiff status in a pending class action lawsuit. The litigation follows a sharp decline in share price, which plummeted from a $46.00 IPO valuation to $14.12.
Investors who suffered losses following the failure of Grail, Inc.’s NHS-Galleri clinical trial have until August 4, 2026, to file as lead plaintiffs. The class action centers on allegations that the company misled shareholders regarding the trial's prospects before a significant market collapse in February.
Investors who purchased ZoomInfo Technologies, Inc. (NASDAQ: GTM) shares between November 3, 2025, and May 11, 2026, face an August 24 deadline to file for lead plaintiff status. This legal action follows a 33% stock price collapse sparked by the company’s sudden reversal in financial guidance and growth projections.
Investors who purchased Microsoft Corporation securities between May 1, 2025, and January 28, 2026, are being urged to contact legal counsel following the filing of a class action lawsuit in the U.S. District Court for the Western District of Washington regarding alleged misrepresentations of the company's AI initiatives.
Investors who bought PicS N.V. shares during the company’s January 2026 IPO face a looming August 4 deadline to join a securities class action. The lawsuit alleges that the digital bank concealed significant credit portfolio deficiencies and a massive loan reclassification that occurred just weeks before the company went public.
Triumph Higher Education Group has acquired the Culinary Institute of Barcelona, marking a strategic expansion into the European market. The deal integrates the innovative, entrepreneur-focused Spanish school into a portfolio that already includes the Auguste Escoffier School of Culinary Arts and the Pacific Institute of Culinary Arts.
Triumph Higher Education Group has expanded its global footprint by acquiring the Culinary Institute of Barcelona, a move that integrates the Spanish school’s innovation-focused methodology into a network already anchored by the Auguste Escoffier School of Culinary Arts and the Pacific Institute of Culinary Arts in Vancouver.
Investors who purchased Intuit Inc. stock between August 22, 2025, and May 20, 2026, are being urged to contact Levi & Korsinsky, LLP regarding a new class action lawsuit. The litigation centers on claims that the firm misled shareholders about the competitive strength and growth trajectory of its TurboTax business.
Insulet Corporation faces a class-action lawsuit as investors seek to recoup losses following a sharp decline in share price. The litigation centers on allegations that the company misled shareholders regarding the manufacturing quality of its Omnipod insulin delivery systems, which were later subject to two major recalls.
A securities class action lawsuit has been filed against Nano-X Imaging Ltd. following a 24.39% stock price collapse on April 20, 2026. Investors allege the company misled shareholders regarding the efficiency and scalability of its Korean chip manufacturing facility, which was ultimately shuttered following significant impairment charges.
Agilisium has secured Select Services Partner status within the Claude Partner Network, formalizing its role in deploying agentic AI for the life sciences sector. The Los Angeles-based firm is integrating Anthropic’s reasoning models into its proprietary FDX framework to support high-stakes clinical and regulatory environments.
A class action lawsuit filed in New York alleges that Megan Holdings Limited operated as a shell company to facilitate a coordinated pump-and-dump scheme. The litigation targets the aquaculture firm’s leadership and underwriters, claiming they misled investors through fabricated operational growth and baseless stock promotion between September 2025 and March 2026.
Investors who purchased Peabody Energy stock between October 14, 2024, and May 4, 2026, face an August 24, 2026, deadline to seek lead plaintiff status in a securities class action. The lawsuit targets alleged misrepresentations made by former executive Marc E. Hathhorn regarding the company’s Centurion mine operations.
Conflict lead: A federal class action lawsuit now targets Brian Grass, the former CFO and interim CEO of Helen of Troy Limited, alleging he misled shareholders regarding the success of the company’s Project Pegasus restructuring program while overseeing the firm’s financial disclosures between April 2024 and October 2025.
Investors who purchased GeneDx Holdings Corp. stock between April 16, 2025, and May 4, 2026, face an August 3, 2026, deadline to seek lead plaintiff status in a newly filed securities class action. The litigation follows a 49.2% single-day share price collapse triggered by disclosures regarding the firm's Fabric Genomics acquisition.
Investors in ADMA Biologics, Inc. are facing an August 10, 2026, deadline to join a securities class action lawsuit. The complaint alleges the company used channel stuffing to artificially inflate revenues for its specialty therapy ASCENIV, masking what may have been a 3% decline as 20% growth.
Lucid Group faces a class action lawsuit following revelations that management touted a repeatable operating cadence while secretly grappling with a month-long delivery halt. Investors claim the company’s February 2026 assurances of structural progress masked a supplier-driven crisis that ultimately triggered a sharp decline in share price.
Investors who purchased Futu Holdings Limited stock between May 24, 2023, and May 27, 2026, face an August 25 deadline to join a class action lawsuit. The litigation follows a sharp 27.5% drop in share price triggered by the revelation of a massive RMB 1.85 billion penalty from Chinese regulators.
Mary Clum, President of AeroVironment’s Space, Cyber & Directed Energy segment, faces a securities class action lawsuit for allegedly misrepresenting the readiness of the company’s $1.7 billion SCAR program. Investors who purchased shares between June 25, 2025, and March 10, 2026, have until July 27, 2026, to seek lead plaintiff status.
Investors who purchased Verra Mobility Corporation stock between February 24 and May 26, 2026, face an August 4 deadline to join a securities class action. The lawsuit alleges that leadership misled shareholders regarding the stability of a critical partnership with Avis Budget Group while internal negotiations were failing.
Investors in Planet Fitness are seeking recourse following a 31.19% plunge in share price, as a new securities class action lawsuit accuses the fitness giant of misleading shareholders about the efficacy of its national marketing campaigns during the critical first-quarter sign-up season between November 2025 and May 2026.
KangJyh Lee, a director at Photronics, Inc. and president of its PDMC division, faces a securities class action lawsuit alleging he misled investors about the company’s high-end IC design pipeline. The complaint claims Lee concealed a significant slowdown in customer tape-outs that ultimately triggered a 36.42% collapse in share price.
